2012
DOI: 10.1016/j.cryobiol.2011.11.001
|View full text |Cite
|
Sign up to set email alerts
|

Structural integrity of collagen and elastin in SynerGraft® decellularized–cryopreserved human heart valves

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
21
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 36 publications
(22 citation statements)
references
References 29 publications
1
21
0
Order By: Relevance
“…19,20 In the field of cardiovascular surgery, for example, a glutaraldehyde treatment is used to eliminate immunogenicity, provide sterility and induce collagen cross-linking which increases tissue strength and flexibility in xenogeneic or allogeneic heart valves. 21 However, the degeneration of glutaraldehyde-fixed valves, with subsequent calcification and tissue failure, was proving to be a major disadvantage of these valvular prostheses.…”
Section: The Concept Of Recellularization and Clinical Usagementioning
confidence: 99%
“…19,20 In the field of cardiovascular surgery, for example, a glutaraldehyde treatment is used to eliminate immunogenicity, provide sterility and induce collagen cross-linking which increases tissue strength and flexibility in xenogeneic or allogeneic heart valves. 21 However, the degeneration of glutaraldehyde-fixed valves, with subsequent calcification and tissue failure, was proving to be a major disadvantage of these valvular prostheses.…”
Section: The Concept Of Recellularization and Clinical Usagementioning
confidence: 99%
“…The Synergraft process uses hypotonic cell lysis, nuclease digestion and isotonic washes but does not incorporate a detergent wash (Gerson et al ., 2012; O’Brien et al ., 1999; Zehr et al ., 2005). The process has, however, been reported to reduce MHC immunoreactivity markedly, indicating reduction in membrane proteins (Elkins et al ., 2001b).…”
Section: Discussionmentioning
confidence: 99%
“…An antigen reduction method process, the SynerGraft™ process was developed by CryoLife Inc (Elkins et al ., 2001a; O’Brien et al ., 1999) and Elkins et al (2001a) were the first to report on very early clinical results of pulmonary allografts treated by the SynerGraft process. This proprietary process involves cell lysis induced by incubation in water and nuclease digestion followed by a multiday isotonic wash‐out phase (Gerson et al ., 2012; O’Brien et al ., 1999). Near complete removal of cells and cellular components was demonstrated through histological and immunocytochemical analysis with no corresponding change in the in vitro biomechanics (Elkins et al ., 2001b).…”
Section: Introductionmentioning
confidence: 99%
“…Removing the cell population from a tissue or organ eliminates the potential for immunogenic rejection while retaining the complex three-dimensional matrix that is critical to tissue and organ function. 10 To date, research has been conducted on many tissue and organ types to provide an alternative option to autografts, from liver, 11 heart valves, 12 cartilage 13 and of particular interest here, in tendon 14,15 and ligament 16,17 tissues. Despite the potential success of decellularised tissues for implantation following tendon or ligament injury, the supply of suitable allograft material from cadavers, or indeed, xenografts from animal sources, will always be the main obstacle in providing an ‘off-the-shelf’ ligament or tendon replacement.…”
Section: Introductionmentioning
confidence: 99%